Table 2 Summary of clinical characteristics and outcomes
Characteristics | Total cases | |
|---|---|---|
Age, years, median [min–max] | 64 [24–84] | 15 |
Sex (%) | 15 | |
Female | 5 (33.3%) | |
Male | 10 (66.7%) | |
Comorbidities | 12 | |
Hypertension | 4 (33.3%) | |
Diabetes mellitus | 3 (25.0%) | |
IHD | 1 (8.3%) | |
Glaucoma | 1 (8.3%) | |
Region (%) | 15 | |
East Asia | 6 (40.0%) | |
United States | 4 (26.7%) | |
Europe | 2 (13.3%) | |
MENA region | 1 (6.7%) | |
Australia | 1 (6.7%) | |
South America | 1 (6.7%) | |
Time from vaccination to symptom onset (%) | 15 | |
0–10 days | 6 (40.0%) | |
11–20 days | 8 (53.3%) | |
21 days or more | 1 (6.7%) | |
Vaccine name (%) | 15 | |
Pfizer and BioNTech | 7 (46.7%) | |
Astra Zeneca | 3 (20.0%) | |
Johnson & Johnson | 2 (13.3%) | |
Sinovac | 2 (13.3%) | |
Moderna | 1 (6.7%) | |
Vaccine dose (%) | 14 | |
First | 8 (57.1%) | |
Second | 6 (42.9%) | |
Clinical findings (%) | 15 | |
Ataxia | 11 (73.3%) | |
Areflexia | 9 (60.0%) | |
Facial nerve palsy/facial weakness | 7 (46.7%) | |
Headache | 3 (20.0%) | |
Limbs weakness | 2 (13.3%) | |
Dizziness | 2 (13.3%) | |
Dysarthria | 1 (6.7%) | |
Ocular manifestations (%) | ||
Diplopia | 11 (73.3%) | 15 |
Ptosis | 4 (26.7%) | |
Restricted abduction | 6 (40.0%) | |
Inability to fully close one or two eyes | 4 (26.7.0%) | |
Absent or abnormal pupil reflex | 3 (20.0%) | |
Side of ocular manifestations (%) | ||
Bilateral | 11 (78.6%) | 14 |
Right | 2 (14.3%) | |
Left | 1 (7.1%) | |
Antibodies profile | 13 | |
Positive anti-GQb1 | 7 (53.8%) | |
Equivalent anti-GQb1 | 1 (7.7%) | |
NCS and EMG | 12 | |
Abnormal findings | 7 (58.3%) | |
Normal | 5 (41.7%) | |
Treatment (%) | 15 | |
IVIg | 13 (86.6%) | |
Physiotherapy | 2 (13.3%) | |
Steroid | 1 (6.7%) | |
Outcome (%) | 15 | |
Complete resolution | 6 (40.0%) | |
Improved | 9 (60.0%) | |